Ameri Hosein, Safari Hossein, Poder Thomas
Health Policy and Management Research Center, Department of Health Services Management, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Health Promotion Research Centre, Iran University of Medical Sciences, Tehran, Iran.
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):1017-1024. doi: 10.1080/14737167.2021.1842734. Epub 2020 Dec 1.
: Short-Form Six-Dimension version 2 (SF-6Dv2) is a multi-attribute utility instrument that can be used in combination with the SF-36v2 (SF-6Dv2) or as an independent instrument in two forms: six questions (SF-6Dv2) and 10 questions (SF-6Dv2). The purpose of this research was to assess the consistency between the results of the SF-6Dv2 and the SF-6Dv2 in patients with breast cancer.: This cross-sectional study was carried out on 418 patients with breast cancer. The degree of agreement between the descriptive systems of instruments was calculated using Spearman's correlation coefficient, global consistency index (GCI), and identically classified index (ICI).: The average size of the Spearman's correlation coefficients between the descriptive systems of instruments was higher than 0.5. The results of the GCI revealed that the level of agreement between dimensions of the two instruments had a mean of 64.9 (range 32.45-86.8). The SF-6Dv2 generates statistically higher values than does the SF-6Dv2, and mean difference between the two instruments was 0.087 for model 3 and 0.027 for model 10.: This study provided evidence that the SF-6Dv2 and the SF-6Dv2 may produce different answers from patients with breast cancer and lead to a small difference in utility values.
简式六维度版本2（SF - 6Dv2）是一种多属性效用工具，可与SF - 36v2（SF - 6Dv2）联合使用，或作为独立工具以两种形式使用：六个问题（SF - 6Dv2）和十个问题（SF - 6Dv2）。本研究的目的是评估乳腺癌患者中SF - 6Dv2和SF - 6Dv2结果之间的一致性。
这项横断面研究对418例乳腺癌患者进行。使用斯皮尔曼相关系数、整体一致性指数（GCI）和同分类指数（ICI）计算工具描述系统之间的一致程度。
工具描述系统之间斯皮尔曼相关系数的平均大小高于0.5。GCI结果显示，两种工具维度之间的一致水平均值为64.9（范围32.45 - 86.8）。SF - 6Dv2产生的统计学值高于SF - 6Dv2，两种工具之间的平均差异对于模型3为0.087，对于模型10为0.027。
本研究提供了证据表明SF - 6Dv2和SF - 6Dv2可能会从乳腺癌患者那里得到不同答案，并导致效用值存在微小差异。
